Drugs / IVAC_W_bre1_uID
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02316457 | Oct 2016 → May 2020 | triple-negative breast carcinoma | BioNTech SE | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVAC_W_bre1_uID | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02316457 ↗ |